Comprehensive Care, Ryan White Funding, Means Survival Benefits at Inner-City Clinic
At an inner city Baltimore HIV clinic serving a primarily poor and black population, the average life expectancy is now 73 years, according to a new 15-year analysis of patient outcomes reported by Johns Hopkins University researchers in Clinical Infectious Diseases. Importantly, long-term survival at the clinic was highly dependent on comprehensive disease management—a mix of expert primary, specialty and supportive health care services—underscoring the importance of funding streams like Ryan White to provide vital resources.
CD4 Counts Not Affected by Alcohol Consumption
Consuming alcohol doesn’t appear to have a deleterious effect on CD4 cell counts among people living with HIV receiving antiretroviral therapy, according to a new Johns Hopkins University study.
September 21, 2012
Thalidomide for HIV-Related IRIS Shows Promise Thalidomide, a historically controversial drug, may hold potential for people living with HIV who experience immune reconstitution inflammatory syndrome (IRIS) and do not respond favorably and quickly to corticosteroids like prednisone, according to a small series of case reports published online ahead of print by the journal AIDS.
September 20, 2012
Boehringer Ingelheim Exits Virology Research
Boehringer Ingelheim, a Germany-based company known for its successful development of two HIV drugs and ongoing study of two hepatitis C medications, is discontinuing its virology research program.
Dolutegravir Regimen Bests Atripla as First-Line HIV Therapy
Dolutegravir, an experimental once-daily integrase inhibitor being developed by ViiV Healthcare and Shionogi, combined with Epzicom, appears to have an efficacy advantage over Atripla among people starting HIV treatment for the first time.
Black Women With HIV and Hep C Less Likely to Die of Liver-Related Disease Black women living with HIV and hepatitis C virus (HCV) are less likely to die of liver disease, compared with white and Latina women coinfected with both viruses, according to a new analysis of the federally funded Women’s Interagency HIV Study (WIHS) published online ahead of print by the journal Hepatology.
September 06, 2012
HIV Treatment Increasing Among Those in Care in U.S. Among people engaged in HIV care in the United States, rates of antiretroviral therapy usage and undetectable viral loads increased substantially between 2000 and 2008, according to new data from the NA-ACCORD study.
Gilead Sciences, Task Force Agree to ADAP Price Discount for Stribild
The AIDS Drug Assistance Program (ADAP) purchase price for the newly approved fixed-dose combination tablet Stribild will be substantially lower than the announced $28,500 wholesale acquisition cost (WAC), as a result of a new pricing agreement reached between Gilead Sciences and the ADAP Crisis Task Force.
Crofelemer for HIV Diarrhea Delayed Again by FDA The U.S. Food and Drug Administration (FDA) has again postponed a decision on approving crofelemer, a compound made from the sap of the Peruvian Dragon’s Blood tree for the treatment of diarrhea in people living with HIV receiving antiretroviral therapy.
September 05, 2012
Too Few People With HIV Take Aspirin to Prevent Heart Attacks and Strokes Most HIV-positive people who should be taking aspirin to prevent a heart attack or stroke are not doing so, according to a University of Alabama at Birmingham (UAB) study published online ahead of print by Clinical Infectious Diseases. In fact, fewer than one in five who met the U.S. criteria for aspirin therapy were taking advantage of the cheap, over-the-counter medication.
September 04, 2012
Norvir-Boosted Reyataz Linked to High Kidney Stone Risk People living with HIV using Norvir (ritonavir)-boosted Reyataz (atazanavir) were roughly ten times more likely to experience kidney stones, compared with those using other Norvir-boosted protease inhibitor (PI)-based regimens, according to a review of patient data conducted by Japanese researchers.
More Treatment News
Have news about HIV? Send press releases, news tips and other announcements to firstname.lastname@example.org.